Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Syndax Pharmaceuticals (SNDX) PT Raised to $51 at Citi, Opens 90d Catalyst Watch
August 5, 2025 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $51.00 (from $46.00) while maintaining a Buy rating.
Opens 90-Day Upside Catalyst Watch ahead of October 25 PDUFA for Revuforjs sNDA in R/R mNPM1 AML.... More


